Arunjyoti Bio Ventures Limited has announced the postponement of its Board Meeting, which was originally scheduled for May 8, 2026. The meeting has been rescheduled to May 12, 2026, due to unavoidable reasons. The intimation regarding this change was communicated to BSE Limited on May 5, 2026, referencing the earlier notice dated May 1, 2026.

Revised Meeting Details

The board meeting will now take place at the company's registered office. The venue and logistical details remain consistent with the original plan, ensuring a formal setting for the directors to deliberate on key financial matters.

Agenda Items

The agenda for the rescheduled meeting remains unchanged. The board will focus on the primary items essential for the company's regulatory compliance and strategic planning:

• Audited Financial Results: Review and approval of audited financial results for the quarter and year ended March 31, 2026
• Additional Business: Consideration of any other business matters with the permission of the Chair

Regulatory Compliance

The intimation was digitally signed by P.B.N. Murthy, Whole-Time Director (DIN: 01445523). This communication ensures transparency and keeps stakeholders informed about the change in schedule. The company continues to adhere to corporate governance standards by promptly notifying the stock exchange of the postponement.

This rescheduled meeting allows Arunjyoti Bio Ventures Limited the necessary time to prepare for the presentation of its annual financial performance to stakeholders and fulfill its regulatory obligations for the fiscal year 2026.

Arunjyoti bio ventures Limited has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting a share acquisition transaction by Chennupati Sarath Kumar. The disclosure, dated April 16, 2026, was submitted to BSE Limited where the company's shares are listed.

Transaction Details

Chennupati Sarath Kumar, who is not part of the promoter or promoter group, acquired shares in the company through open market transactions. The acquisition was executed over a period spanning from April 13, 2026, to April 16, 2026.

Shareholding Pattern Changes

The transaction resulted in an increase in Chennupati Sarath Kumar's stake in Arunjyoti Bio Ventures Limited. His shareholding position changed following the completion of the acquisition.

Company Capital Structure

The company's equity share capital structure remained unchanged following this transaction. Arunjyoti Bio Ventures Limited maintains its existing capital base without any alterations to the total number of shares or their face value.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations governing substantial acquisition and disposal of shares. The transaction falls under the purview of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates disclosure when shareholding changes exceed specified thresholds. The filing ensures transparency and keeps investors informed about significant changes in shareholding patterns of listed companies.